{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:47:30Z","timestamp":1795236450686,"version":"4.10.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitor (ICI) use remains a challenge in patients with solid organ allografts as most would undergo rejection. In a melanoma patient in whom programmed-death 1 (PD-1) blockade resulted in organ rejection and colitis, the addition of the mTOR inhibitor sirolimus resulted in ongoing anti-tumor efficacy while promoting allograft tolerance. Strong granzyme B<jats:sup>+<\/jats:sup>, interferon (IFN)-\u03b3<jats:sup>+<\/jats:sup> CD8<jats:sup>+<\/jats:sup> cytotoxic T cell and circulating regulatory T (T<jats:sub>reg<\/jats:sub>) cell responses were noted during allograft rejection, along with significant eosinophilia and elevated serum IL-5 and eotaxin levels. Co-treatment with sirolimus abated cytotoxic T cell numbers and eosinophilia, while elevated T<jats:sub>reg<\/jats:sub> cell numbers in the peripheral blood were maintained. Interestingly, numbers of IFN-\u03b3<jats:sup>+<\/jats:sup> CD4<jats:sup>+<\/jats:sup> T cells and serum IFN-\u03b3 levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy. Thus, our results indicate that sirolimus has the potential to uncouple anti-PD-1 therapy toxicity and efficacy.<\/jats:p>","DOI":"10.1038\/s41467-019-12628-1","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T12:05:58Z","timestamp":1571313958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation"],"prefix":"10.1038","volume":"10","author":[{"given":"Khashayar","family":"Esfahani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tho-Alfakar","family":"Al-Aubodah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jean","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Bhulaiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4124","authenticated-orcid":false,"given":"Tomoko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Cailhier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciriaco A.","family":"Piccirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"12628_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med 50, 165 (2018).","journal-title":"Exp. Mol. Med"},{"key":"12628_CR2","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1503\/cmaj.180870","volume":"191","author":"K Esfahani","year":"2019","unstructured":"Esfahani, K., Meti, N., Miller, W. H. Jr. & Hudson, M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ 191, E40\u2013E46 (2019).","journal-title":"CMAJ"},{"key":"12628_CR3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","volume":"30","author":"GM Delgoffe","year":"2009","unstructured":"Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832\u2013844 (2009).","journal-title":"Immunity"},{"key":"12628_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.immuni.2010.06.002","volume":"32","author":"K Lee","year":"2010","unstructured":"Lee, K. et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743\u2013753 (2010).","journal-title":"Immunity"},{"key":"12628_CR5","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.3389\/fimmu.2018.03036","volume":"9","author":"S Roy","year":"2018","unstructured":"Roy, S., Rizvi, Z. A. & Awasthi, A. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. Front Immunol. 9, 3036 (2018).","journal-title":"Front Immunol."},{"key":"12628_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-065X.2012.01152.x","volume":"249","author":"AT Waickman","year":"2012","unstructured":"Waickman, A. T. & Powell, J. D. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249, 43\u201358 (2012).","journal-title":"Immunol. Rev."},{"key":"12628_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","volume":"24","author":"LE Aguirre","year":"2019","unstructured":"Aguirre, L. E., Guzman, M. E., Lopes, G. & Hurley, J. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 24, 394\u2013401 (2019).","journal-title":"Oncologist"},{"key":"12628_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab, N. et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J. Immunother. Cancer 7, 106 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"12628_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","volume":"31","author":"P De Bruyn","year":"2019","unstructured":"De Bruyn, P. et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr. Opin. Oncol. 31, 54\u201364 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"12628_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2018.36.5_suppl.41","volume":"36","author":"NA Hassan","year":"2018","unstructured":"Hassan, N. A. et al. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature. J. Clin. Oncol. 36, 41\u201341 (2018).","journal-title":"J. Clin. Oncol."},{"key":"12628_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra0902927","volume":"363","author":"BJ Nankivell","year":"2010","unstructured":"Nankivell, B. J. & Alexander, S. I. Rejection of the kidney allograft. N. Engl. J. Med 363, 1451\u20131462 (2010).","journal-title":"N. Engl. J. Med"},{"key":"12628_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JOP.2017.027326","volume":"14","author":"M Sadaat","year":"2018","unstructured":"Sadaat, M. & Jang, S. Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy. J. Oncol. Pr. 14, 198\u2013199 (2018).","journal-title":"J. Oncol. Pr."},{"key":"12628_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett, R., Barta, V. S. & Jhaveri, K. D. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N. Engl. J. Med 376, 191\u2013192 (2017).","journal-title":"N. Engl. J. Med"},{"key":"12628_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","volume":"40","author":"AS Kittai","year":"2017","unstructured":"Kittai, A. S., Oldham, H., Cetnar, J. & Taylor, M. Immune checkpoint inhibitors in organ transplant patients. J. Immunother. 40, 277\u2013281 (2017).","journal-title":"J. Immunother."},{"key":"12628_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","volume":"87","author":"AW Kubica","year":"2012","unstructured":"Kubica, A. W. & Brewer, J. D. Melanoma in immunosuppressed patients. Mayo Clin. Proc. 87, 991\u20131003 (2012).","journal-title":"Mayo Clin. Proc."},{"key":"12628_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/01.TP.0000160759.85080.2E","volume":"79","author":"E Lazzeri","year":"2005","unstructured":"Lazzeri, E. et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 79, 1215\u20131220 (2005).","journal-title":"Transplantation"},{"key":"12628_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/j.1600-6143.2004.00525.x","volume":"4","author":"M Rotondi","year":"2004","unstructured":"Rotondi, M. et al. High pretransplant serum levels of CXCL10\/IP-10 are related to increased risk of renal allograft failure. Am. J. Transpl. 4, 1466\u20131474 (2004).","journal-title":"Am. J. Transpl."},{"key":"12628_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nyas.12756","volume":"1346","author":"A Perl","year":"2015","unstructured":"Perl, A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann. N. Y Acad. Sci. 1346, 33\u201344 (2015).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"12628_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"12628_CR20","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H Populo","year":"2012","unstructured":"Populo, H., Lopes, J. M. & Soares, P. The mTOR signalling pathway in human cancer. Int J. Mol. Sci. 13, 1886\u20131918 (2012).","journal-title":"Int J. Mol. Sci."},{"key":"12628_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/15384047.2018.1435221","volume":"19","author":"X Wu","year":"2018","unstructured":"Wu, X. et al. PI3K\/AKT\/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. Cancer Biol. Ther. 19, 584\u2013589 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"12628_CR22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/sj.jid.5701074","volume":"128","author":"M Karbowniczek","year":"2008","unstructured":"Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H. & Henske, E. P. mTOR is activated in the majority of malignant melanomas. J. Invest Dermatol 128, 980\u2013987 (2008).","journal-title":"J. Invest Dermatol"},{"key":"12628_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev.pathmechdis.3.121806.151508","volume":"3","author":"LD Cornell","year":"2008","unstructured":"Cornell, L. D., Smith, R. N. & Colvin, R. B. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev. Pathol. 3, 189\u2013220 (2008).","journal-title":"Annu Rev. Pathol."},{"key":"12628_CR24","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson, E. J. et al. Tumor regression and allograft rejection after administration of anti-PD-1. N. Engl. J. Med 374, 896\u2013898 (2016).","journal-title":"N. Engl. J. Med"},{"key":"12628_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/00007890-198606000-00008","volume":"41","author":"MR Weir","year":"1986","unstructured":"Weir, M. R. et al. The prognostic value of the eosinophil in acute renal allograft rejection. Transplantation 41, 709\u2013712 (1986).","journal-title":"Transplantation"},{"key":"12628_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1290::AID-IMMU1290>3.0.CO;2-H","volume":"30","author":"MY Braun","year":"2000","unstructured":"Braun, M. Y. et al. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma. Eur. J. Immunol. 30, 1290\u20131296 (2000).","journal-title":"Eur. J. Immunol."},{"key":"12628_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","volume":"81","author":"A Bernard-Tessier","year":"2017","unstructured":"Bernard-Tessier, A. et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur. J. Cancer 81, 135\u2013137 (2017).","journal-title":"Eur. J. Cancer"},{"key":"12628_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/resp.12554","volume":"20","author":"W Hua","year":"2015","unstructured":"Hua, W. et al. Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice. Respirology 20, 1055\u20131065 (2015).","journal-title":"Respirology"},{"key":"12628_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/eji.201142327","volume":"42","author":"D Bernardo","year":"2012","unstructured":"Bernardo, D. et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and Tcells they stimulate. Eur. J. Immunol. 42, 1337\u20131353 (2012).","journal-title":"Eur. J. Immunol."},{"key":"12628_CR30","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.4049\/jimmunol.0902464","volume":"184","author":"K Guilloteau","year":"2010","unstructured":"Guilloteau, K. et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1\u03b1, and TNF-\u03b1 recapitulates some features of psoriasis. J. Immunol. 184, 5263\u20135270 (2010).","journal-title":"J. Immunol."},{"key":"12628_CR31","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani, K. & Miller, W. H. Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N. Engl. J. Med 376, 1989\u20131991 (2017).","journal-title":"N. Engl. J. Med"},{"issue":"Suppl 1","key":"12628_CR32","first-page":"S34","volume":"13","author":"J Kaden","year":"2000","unstructured":"Kaden, J. & Priesterjahn, R. Increasing urinary IL-6 levels announce kidney graft rejection. Transpl. Int 13(Suppl 1), S34\u2013S41 (2000).","journal-title":"Transpl. Int"},{"key":"12628_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/ndt\/12.4.753","volume":"12","author":"J Waiser","year":"1997","unstructured":"Waiser, J. et al. Interleukin-6 expression after renal transplantation. Nephrol. Dial. Transpl. 12, 753\u2013759 (1997).","journal-title":"Nephrol. Dial. Transpl."},{"key":"12628_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1600-6143.2011.03770.x","volume":"12","author":"X Zhao","year":"2012","unstructured":"Zhao, X. et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am. J. Transpl. 12, 90\u2013101 (2012).","journal-title":"Am. J. Transpl."},{"key":"12628_CR35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1172\/JCI17129","volume":"112","author":"RM McLoughlin","year":"2003","unstructured":"McLoughlin, R. M. et al. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest 112, 598\u2013607 (2003).","journal-title":"J. Clin. Invest"},{"key":"12628_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0002-9440(10)63960-0","volume":"158","author":"PF Halloran","year":"2001","unstructured":"Halloran, P. F. et al. Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. Am. J. Pathol. 158, 215\u2013226 (2001).","journal-title":"Am. J. Pathol."},{"key":"12628_CR37","doi-asserted-by":"crossref","first-page":"175883401774974","DOI":"10.1177\/1758834017749748","volume":"10","author":"N Karachaliou","year":"2018","unstructured":"Karachaliou, N. et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther. Adv. Med Oncol. 10, 1758834017749748 (2018).","journal-title":"Ther. Adv. Med Oncol."},{"key":"12628_CR38","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1074\/jbc.M115.664995","volume":"291","author":"B Kroczynska","year":"2016","unstructured":"Kroczynska, B. et al. Interferon \u03b3 (IFN\u03b3) signaling via mechanistic target of rapamycin complex 2 (mTORC2) and regulatory effects in the generation of type II interferon biological responses. J. Biol. Chem. 291, 2389\u20132396 (2016).","journal-title":"J. Biol. Chem."},{"key":"12628_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/eji.201445086","volume":"45","author":"R Setoguchi","year":"2015","unstructured":"Setoguchi, R., Matsui, Y. & Mouri, K. mTOR signaling promotes a robust and continuous production of IFN-\u03b3 by human memory CD8+ T cells and their proliferation. Eur. J. Immunol. 45, 893\u2013902 (2015).","journal-title":"Eur. J. Immunol."},{"key":"12628_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ni.3205","volume":"16","author":"X Su","year":"2015","unstructured":"Su, X. et al. Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat. Immunol. 16, 838\u2013849 (2015).","journal-title":"Nat. Immunol."},{"key":"12628_CR41","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2217\/imt.14.84","volume":"6","author":"NM Chapman","year":"2014","unstructured":"Chapman, N. M. & Chi, H. mTOR signaling, Tregs and immune modulation. Immunotherapy 6, 1295\u20131311 (2014).","journal-title":"Immunotherapy"},{"key":"12628_CR42","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.4049\/jimmunol.1100269","volume":"186","author":"E d\u2019Hennezel","year":"2011","unstructured":"d\u2019Hennezel, E., Yurchenko, E., Sgouroudis, E., Hay, V. & Piccirillo, C. A. Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3+ cells. J. Immunol. 186, 6788\u20136797 (2011).","journal-title":"J. Immunol."},{"key":"12628_CR43","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1172\/JCI45138","volume":"122","author":"S Gupta","year":"2012","unstructured":"Gupta, S. et al. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J. Clin. Invest 122, 2395\u20132404 (2012).","journal-title":"J. Clin. Invest"},{"key":"12628_CR44","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni1263","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142\u20131151 (2005).","journal-title":"Nat. Immunol."},{"key":"12628_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.coi.2010.01.018","volume":"22","author":"EL Pearce","year":"2010","unstructured":"Pearce, E. L. Metabolism in T cell activation and differentiation. Curr. Opin. Immunol. 22, 314\u2013320 (2010).","journal-title":"Curr. Opin. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12628-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:39:54Z","timestamp":1671241194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12628-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["12628"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-12628-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Khashayar Esfahani reports receiving speaker\u2019s fees from Bristol-Myers Squibb, outside the submitted work. Wilson Miller reports receiving grants from Bristol-Myers Squibb, Merck, Roche, Novartis, AstraZeneca, Amgen, Bayer, MedImmune and GlaxoSmithKline, outside the submitted work, as well as personal fees from Bristol-Myers Squibb, Merck, Roche, Novartis, Amgen and GlaxoSmithKline. Marie Hudson reports receiving a grant from Bristol-Myers Squibb, outside the submitted work. Nathalie Johnson has received honoraria and consulting fees from Bristol-Myers Squibb and Merck Canada. The remaining authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4712"}}